On 15 January, the members of the European Prevention of Alzheimer's Dementia (EPAD) research initiative announced the recruitment of the 2,000 research participant in its Longitudinal Cohort Study (LCS). EPAD is a Europe-wide collaboration aiming to improve the understanding of the early stages of Alzheimer’s disease. EPAD is set up to recruit from existing cohort studies as well as clinics across Europe. EPAD has established the first pan-European register including research participants aged 50 or over across the dementia risk spectrum. From this register, individuals who do not have dementia are invited to join the EPAD LCS, involving standardised tests and follow-up over several years. Currently, EPAD has 29 study sites up and running across 9 European countries (i.e. Belgium, France, Greece, Italy, Netherlands, Spain, Switzerland, Sweden and UK). The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.